We found that the frequency of CDKN2A deletion was significantly and consistently associated with an increased risk of local invasion (p<0.001) and distant metastasis of various cancers without lymph metastasis (p<0.025; Figure S1A), especially for head and neck squamous cell carcinoma (HNSC), kidney clear cell carcinoma (KIRC), pancreas adenocarcinoma (PAAD), skin cutaneous melanoma (SKCM), and stomach adenocarcinoma (STAD/GC) (Figure S1B). This evidence concerns the gene CDKN2A and cancer.